Literature DB >> 23962556

MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2.

Chonglin Luo1, Patrick R Merz, Yiwei Chen, Elke Dickes, Armin Pscherer, Dirk Schadendorf, Stefan B Eichmüller.   

Abstract

The microRNA miR-101 has been reported to be a tumor suppressor. Here we show that low expression of miR-101 is associated with poor survival in stage IV melanoma patients. We identified microphthalmia-associated transcription factor (MITF) as a direct target of miR-101. In melanoma cells, overexpression of miR-101 downregulated protein levels of MITF and a previously reported target protein, enhancer of zeste homolog 2 (EZH2). Functional assays showed that miR-101 suppressed invasion and proliferation - an outcome that could be phenocopied by siRNA knockdown of MITF and EZH2. Our data suggest that miR-101 might have a beneficial role in melanoma.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Enhancer of zeste homolog 2; Invasion; Melanoma; MicroRNA; Microphthalmia-associated transcription factor

Mesh:

Substances:

Year:  2013        PMID: 23962556     DOI: 10.1016/j.canlet.2013.08.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.

Authors:  Matthew L Fisher; Gautam Adhikary; Dan Grun; David M Kaetzel; Richard L Eckert
Journal:  Mol Carcinog       Date:  2015-12-23       Impact factor: 4.784

Review 2.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; Dennis R Warner; Irina A Smolenkova; M Michele Pisano; Robert M Greene
Journal:  Reprod Toxicol       Date:  2016-12-05       Impact factor: 3.143

4.  MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.

Authors:  Yang Liu; Juan Tan; Shuangyan Ou; Jun Chen; Limin Chen
Journal:  Invest New Drugs       Date:  2019-03-30       Impact factor: 3.850

Review 5.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

Review 6.  Pro-survival role of MITF in melanoma.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  J Invest Dermatol       Date:  2014-08-21       Impact factor: 8.551

7.  Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.

Authors:  L Bizzozero; D Cazzato; D Cervia; E Assi; F Simbari; F Pagni; C De Palma; A Monno; C Verdelli; P R Querini; V Russo; E Clementi; C Perrotta
Journal:  Cell Death Differ       Date:  2013-12-06       Impact factor: 15.828

8.  Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.

Authors:  Ming Gao; Yuan Chang; Xiuyong Wang; Chao Ban; Fan Zhang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 9.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

Review 10.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.